High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. Here's why these two high-yield ...

Biotech-stock investing has one tough test for success - and it's about to get easier ...

That's because FDA flexibility can mean approval for drugs that are too dangerous or simply do not work. Skorney cited a drug called Oxbryta from Pfizer (PFE), which was approved to treat the blood ...

Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good morning, and welcome to Fulcrum Therapeutics Third Quarter ...

Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents ...

Detailed price information for Fulcrum Therapeutics Inc (FULC-Q) from The Globe and Mail including charting and trades.

As we reported this morning, the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon could see a dramatic uptick in sales with Pfizer's marketing ...